Page 21 - Crispr Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Crispr therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Crispr Therapeutics Today - Breaking & Trending Today

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $68.39 Consensus PT from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Hold” from the eighteen research firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating on the company. The […] ....

Tradewinds Capital Management , Morgan Stanley , Headlands Technologies , Geneos Wealth Management Inc , Cantor Fitzgerald , Bluepath Capital Management , Get Free Report , Marketbeat Ratings , Wealth Management , Capital Management , Get Free , Crispr Therapeutics , Nasdaq Crsp ,

ARK Investment Management LLC Sells 175,329 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

ARK Investment Management LLC cut its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,163,118 shares of the company’s stock after selling 175,329 shares during the quarter. CRISPR […] ....

Pinnacle Holdings , Eversource Wealth Advisors , Royal Bank , Securities Exchange Commission , Geneos Wealth Management Inc , Ark Investment Management , Needham Company , Investment Management , Therapeutics Company Profile , Free Report , Wealth Management , Source Wealth Advisors , Get Free Report , Crispr Therapeutics , Nasdaq Crsp , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Hold" by Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus recommendation of “Hold” from the eighteen brokerages that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. The average […] ....

Geneos Wealth Management Inc , Tradewinds Capital Management , Headlands Technologies , Cantor Fitzgerald , Morgan Stanley , Bluepath Capital Management , Therapeutics Company Profile , Get Free Report , Marketbeat Ratings , Wealth Management , Capital Management , Get Free , Crispr Therapeutics , Nasdaq Crsp ,

ARK Investment Management LLC Has $325.13 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

ARK Investment Management LLC lowered its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,163,118 shares of the company’s stock after selling 175,329 shares during the period. […] ....

Exchange Commission , Cetera Advisor Networks , Cantor Fitzgerald , Morgan Stanley , Venturi Wealth Management , Vontobel Holding Ltd , Ark Investment Management , Voya Investment Management , Therapeutics Company Profile , Investment Management , Free Report , Wealth Management , Advisor Networks , Get Free Report , Crispr Therapeutics , Nasdaq Crsp , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,